GeneReviews^® [Internet].

Clinical Description

Type II collagen is an essential component of the cartilage extracellular matrix, and of major importance in endochondral bone formation, growth, and normal joint function. It is also necessary for normal development and function of the eye and the inner ear. Type II collagen disorders encompass a diverse group of clinical phenotypes characterized by skeletal dysplasia, ocular manifestations (e.g., cataract, myopia, subluxation of the lens, vitreous abnormalities, retinal detachment), hearing impairment, and orofacial features [Nishimura et al 2005,Kannu et al 2012,Spranger et al 2012a,Terhal et al 2015,Savarirayan et al 2019].

The spectrum of severity ranges from severe perinatal-lethal disorders to milder conditions presenting in adulthood with premature arthrosis as the primary feature. Considerable phenotypic overlap notwithstanding, discriminating features can aid in the specific diagnosis (seeTable 1). The following individual phenotypes are recognized in the 2023 revision of the Nosology of Genetic Skeletal Disorders [Unger et al 2023], and can be grouped according to severity.

Most severe (often lethal perinatally)

• Achondrogenesis,COL2A1-related (formerly type II, type Langer-Saldino)
• Hypochondrogenesis,COL2A1-related
• Platyspondylic dysplasia, type Torrance,COL2A1-related

Severe / moderately severe (neonatal presentation)

• Kniest dysplasia,COL2A1-related
• Spondyloepiphyseal dysplasia congenita (SEDC),COL2A1-related
• Spondyloepimetaphyseal dysplasia (SEMD),COL2A1-related

Intermediate (neonatal/childhood/adolescent presentation)

• Spondyloperipheral dysplasia,COL2A1-related
• Spondyloepiphyseal dysplasia (SED) with metatarsal shortening,COL2A1-related
• Stickler syndrome,COL2A1-related

Mild (adolescent/adult presentation)

• Mild spondyloepiphyseal dysplasia (SED) with premature arthrosis

Genotype-Phenotype Correlations

There is currently no cleargenotype-phenotype correlation in type II collagen disorders, and there is significant phenotypic overlap. However, data do support some general rules [Nishimura et al 2005,Hoornaert et al 2006,Terhal et al 2015,Barat-Houari et al 2016b,Barat-Houari et al 2016c] (see alsoLeiden Open Variation Database [LOVD]). Most pathogenicCOL2A1 variants involve the triple helixdomain.

• Missense variants in the Gly position of the Gly-X-Y repeat motif cause substitution of glycine to a bulkier amino acid, interfering with triple helix formation. Thisdominant-negative effect is generally seen in the more severeCOL2A1-related disorders (e.g., achondrogenesis; platyspondylic dysplasia, type Torrance; SEDC; and SEMD).
• In Kniest dysplasia,COL2A1-related,exon skipping is more common [Barat-Houari et al 2016b,Barat-Houari et al 2016c], and it appears thatsplicing variants impose a higher risk for ophthalmologic complications and hearing loss [Terhal et al 2015].
• Arginine-to-cysteine substitutions are most often associated with non-lethal phenotypes [Hoornaert et al 2006]. A p.Arg275Cys substitution in the Y position of the Gly-X-Y repeat motif causes SED with metatarsal shortening,COL2A1-related [Hoornaert et al 2007].
• In Stickler syndrome,COL2A1-related,nonsense and frameshift variants dominate, introducing a premature termination codon leading tohaploinsufficiency [Richards et al 2006].

Penetrance

Penetrance in type II collagen disorders is high, if not complete; only rare instances of apparently reducedpenetrance have been reported [Barat-Houari et al 2016b]. However, the milder disorders have age-dependent phenotypic manifestations, and wide inter- and intrafamilial phenotypic variation has been reported [Liberfarb et al 2003,Nakashima et al 2016]. At present, knowledge of underlying mechanisms is limited, but the phenotypic variation is likely caused by environmental factors and polymorphisms in disease-modifying genes and/or regulatory elements [Bell et al 1997,Bi et al 1999,Liberfarb et al 2003,Kannu et al 2010,Nakashima et al 2016,Yasuda et al 2017].

Nomenclature

Achondrogenesis,COL2A1-related, was formerly known as achondrogenesis type II or achondrogenesis, type Langer-Saldino.

SED with metatarsal shortening,COL2A1-related, was formerly known as Czech dysplasia.

Prevalence

The exact prevalence of type II collagen disorders is not known. However, Stickler syndrome,COL2A1-related, may be the most common type II collagen disorder; the overall incidence of all types of Stickler syndrome is estimated at 1:10,000 [Rose et al 2001].

Table 2a.

View in own window

Table 2b.

View in own window

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with a type II collagen disorder, the evaluations summarized inTable 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This ideally involves multidisciplinary care by specialists in relevant fields (seeTable 4).

Surveillance

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized inTable 5 are recommended.

Agents/Circumstances to Avoid

In individuals with cervical spine instability, extreme neck extension and neck flexion and contact sports should be avoided.

In case of general anesthesia, the cervical spine should be assessed by imaging prior to the procedure [White et al 2017].

Evaluation of Relatives at Risk

It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from recommended surveillance in order to avoid/prevent common complications.

SeeGenetic Counseling for issues related to testing of at-risk relatives forgenetic counseling purposes.

Pregnancy Management

In individuals with a small pelvis, delivery by cesarean section should be considered. However, each individual should be assessed by an obstetrician familiar with skeletal dysplasia [Savarirayan et al 2018].

Therapies Under Investigation

SearchClinicalTrials.gov in the US andEU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

Type II collagen disorders are typically inherited in anautosomal dominant manner.

Autosomal recessive inheritance of type II collagen disorders has been reported in several families to date [Tham et al 2015,Barat-Houari et al 2016a,Al-Sannaa et al 2020,Girisha et al 2020,Zhang et al 2021,Tüysüz et al 2023].

Autosomal Dominant Inheritance – Risk to Family Members

Parents of aproband

• Most individuals diagnosed with a severe type II collagen disorder have the disorder as the result of ade novopathogenic variant. The overall proportion of individuals with a type II collagen disorder caused by ade novoCOL2A1 pathogenic variant is unknown.
• Many individuals diagnosed with a milder type II collagen disorder have an affected parent. Clinical variability within a family can be extensive; however, severe and mild forms are not seen in family members with the samepathogenic variant (i.e., the specific type II collagen diagnosis appears to run true in a family, but withvariable expressivity).
• If theproband appears to be the only affected family member (i.e., asimplex case),molecular genetic testing is recommended for the parents of the proband to evaluate their genetic status and informrecurrence risk assessment. Note: A proband may appear to be the only affected family member because of failure to recognize the disorder in mildly affected family members. Therefore,de novo occurrence of aCOL2A1pathogenic variant in the proband cannot be confirmed unless molecular genetic testing has demonstrated that neither parent has theCOL2A1 pathogenic variant.
• If thepathogenic variant identified in theproband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:
  • Theproband has ade novopathogenic variant.
  • Theproband inherited apathogenic variant from a parent with gonadal (or somatic and gonadal)mosaicism * [Nagendran et al 2012,Okamoto et al 2012,Stevenson et al 2012,Yamamoto et al 2020,Morrison et al 2020]. Note: Testing of parental leukocyte DNA may not detect all instances ofsomatic mosaicism and will not detect a pathogenic variant that is present in the germ (gonadal) cells only.
    * A parent with somatic andgonadal mosaicism for aCOL2A1pathogenic variant may be mildly/minimally affected.

Sibs of aproband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:

• If a parent of theproband is affected and/or is known to have theCOL2A1pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.
• Penetrance in type II collagen disorders is high; however,intrafamilial variability amongheterozygous family members can be extensive. Note: Severe and mild forms are not seen in family members with the samepathogenic variant (i.e., the specific type II collagen diagnosis appears to run true in a family, but withvariable expressivity).
• If theCOL2A1pathogenic variant identified in theproband cannot be detected in the leukocyte DNA of either parent, therecurrence risk to sibs is slightly greater than that of the general population because of the possibility of parentalgonadal mosaicism [Nagendran et al 2012,Okamoto et al 2012,Stevenson et al 2012,Morrison et al 2020,Yamamoto et al 2020].
• If the parents have not been tested for theCOL2A1pathogenic variant but are clinically unaffected, the risk to the sibs of aproband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for a type II collagen disorder because of the possibility of reducedpenetrance in aheterozygous parent and the possibility of parentalgonadal mosaicism.

Offspring of aproband

• Each child of an individual with a type II collagen disorder has a 50% chance of inheriting theCOL2A1pathogenic variant.
• Because many individuals with short stature have reproductive partners with short stature, offspring of individuals with a type II collagen disorder may be at risk of havingdouble heterozygosity for two dominantly inherited bone growth disorders. The phenotypes of these individuals are distinct from those of the parents, and the affected individuals may have serious sequelae and poor outcomes [Unger et al 2001,Flynn & Pauli 2003].

Other family members. The risk to other family members depends on the status of theproband's parents: if a parent has thepathogenic variant, the parent's family members may be at risk.

Autosomal Recessive Inheritance – Risk to Family Members

Parents of aproband

• The parents of an affected individual are presumed to beheterozygous for aCOL2A1pathogenic variant.
• Molecular genetic testing is recommended for the parents of aproband to confirm that both parents areheterozygous for aCOL2A1pathogenic variant and to allow reliablerecurrence risk assessment.
• If apathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, it is possible that one of the pathogenic variants identified in theproband occurred as ade novo event in the proband or as apostzygoticde novo event in a mosaic parent [Jónsson et al 2017]. If the proband appears to havehomozygous pathogenic variants (i.e., the same two pathogenic variants), additional possibilities to consider include:
  • A single- or multiexondeletion in theproband that was not detected bysequence analysis and that resulted in the artifactual appearance of homozygosity;
  • Uniparental isodisomy for the parentalchromosome with thepathogenic variant that resulted in homozygosity for the pathogenic variant in theproband.
• In the families described byTham et al [2015] andBarat-Houari et al [2016a], oneheterozygous father presented with high myopia, asymmetric lower limbs, and average stature; one heterozygous mother was 154 cm tall; and the two other heterozygous parents were of normal stature.

Sibs of aproband

• If both parents are known to beheterozygous for aCOL2A1pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of thefamilial pathogenic variants.
• Heterozygous sibs are predicted to be either unaffected or mildly affected. Homozygous sibs will be affected in a manner similar to the affected individual but, because ofvariable expressivity, may have a more or less severe clinical outcome.

Offspring of aproband. Unless an affected individual's reproductive partner also hasCOL2A1pathogenic variant(s), the proband's offspring will be obligate heterozygotes for a pathogenic variant inCOL2A1.

Related Genetic Counseling Issues

See Management,Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offergenetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected.

Prenatal Testing and Preimplantation Genetic Testing

Once theCOL2A1pathogenic variant(s) have been identified in an affected family member, prenatal andpreimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal andpreimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.

Acknowledgments

Dr Supriya Raj provided help with the tables, references, and proofreading.

Revision History

• 24 October 2024 (sw) Comprehensive update posted live
• 25 April 2019 (sw) Review posted live
• 22 January 2019 (rs) Original submission

Literature Cited

• AckeFR, DhoogeIJ, MalfaitF, De LeenheerEM. Hearing impairment in Stickler syndrome: a systematic review.Orphanet J Rare Dis.2012;7:84. [PMC free article: PMC3551705] [PubMed: 23110709]
• Al-SannaaNA, HoornaertKP, Van LaerL, Al-AbdulwahedHY, MortierG. Spondylo-epiphyseal dysplasia in two sibs due to a homozygous splicing variant in COL2A1.Eur J Med Genet.2020;63:104059. [PubMed: 32896647]
• Barat-HouariM, BaujatG, Tran Mau ThemF, FabreA, GenevièveD, TouitouI.Confirmation of autosomal recessive inheritance of COL2A1 mutations in spondyloepiphyseal dysplasia congenita: lessons for genetic counseling.Am J Med Genet A.2016a;170A:263-5. [PubMed: 26358419]
• Barat-HouariM, DumontB, FabreA, ThemFT, AlembikY, AlessandriJL, AmielJ, AudebertS, Baumann-MorelC, BlanchetP, BiethE, BrechardM, BusaT, CalvasP, CapriY, CartaultF, ChassaingN, CiorcaV, CoubesC, DavidA, DelezoideAL, Dupin-DeguineD, El ChehadehS, FaivreL, GiulianoF, GoldenbergA, IsidorB, JacquemontML, JuliaS, KaplanJ, LacombeD, LebrunM, MarlinS, Martin-CoignardD, MartinovicJ, MasurelA, MelkiJ, Mozelle-NivoixM, NguyenK, OdentS, PhilipN, PinsonL, PlessisG, QuélinC, ShaefferE, SigaudyS, ThauvinC, TillM, TouraineR, VigneronJ, BaujatG, Cormier-DaireV, Le MerrerM, GenevièveD, TouitouI. The expanding spectrum of COL2A1 gene variants in 136 patients with a skeletal dysplasia phenotype.Eur J Hum Genet.2016b;24:992-1000. [PMC free article: PMC5070901] [PubMed: 26626311]
• Barat-HouariM, SarrabayG, GatinoisV, FabreA, DumontB, GenevieveD, TouitouI.Mutation update for COL2A1 gene variants associated with type II collagenopathies.Hum Mutat.2016c;37:7-15. [PubMed: 26443184]
• BellDM, LeungKK, WheatleySC, NgLJ, ZhouS, LingKW, ShamMH, KoopmanP, TamPP, CheahKS. SOX9 directly regulates the type-II collagen gene.Nat Genet.1997;16:174-8. [PubMed: 9171829]
• BiW, DengJM, ZhangZ, BehringerRR, de CrombruggheB. Sox9 is required for cartilage formation.Nat Genet.1999;22:85-9. [PubMed: 10319868]
• CastoriM, BrancatiF, ScanderbegAC, DallapiccolaB. Hypochondrogenesis.Pediatr Radiol.2006;36:460-1. [PubMed: 16432703]
• FlynnMA, PauliRM. Double heterozygosity in bone growth disorders: four new observations and review.Am J Med Genet A.2003;121A:193-208. [PubMed: 12923858]
• GirishaKM, BhavaniGS, ShahH, MoirangthemA, ShuklaA, KimOH, NishimuraG, MortierGR. Biallelic variants p.Arg1133Cys and p.Arg1379Cys in COL2A1: further delineation of phenotypic spectrum of recessive type 2 collagenopathies.Am J Med Genet A.2020;182:338-47. [PubMed: 31755234]
• HandaA, GrigelionieneG, NishimuraG. Radiologic features of type II and type XI collagenopathies.Radiographics.2021;41:192-209. [PubMed: 33186059]
• HoornaertKP, DewinterC, VereeckeI, BeemerFA, CourtensW, FryerA, FryssiraH, LeesM, Müllner-EidenböckA, RimoinDL, SideriusL, Superti-FurgaA, TempleK, WillemsPJ, ZanklA, ZweierC, De PaepeA, CouckeP, MortierGR. The phenotypic spectrum in patients with arginine to cysteine mutations in the COL2A1 gene.J Med Genet.2006;43:406-13. [PMC free article: PMC2564515] [PubMed: 16155195]
• HoornaertKP, MarikI, KozlowskiK, ColeT, Le MerrerM, LeroyJG, CouckePJ, SillenceD, MortierGR. Czech dysplasia metatarsal type: another type II collagen disorder.Eur J Hum Genet.2007;15:1269-75. [PubMed: 17726487]
• JónssonH, SulemP, KehrB, KristmundsdottirS, ZinkF, HjartarsonE, HardarsonMT, HjorleifssonKE, EggertssonHP, GudjonssonSA, WardLD, ArnadottirGA, HelgasonEA, HelgasonH, GylfasonA, JonasdottirA, JonasdottirA, RafnarT, FriggeM, StaceySN, Th MagnussonO, ThorsteinsdottirU, MassonG, KongA, HalldorssonBV, HelgasonA, GudbjartssonDF, StefanssonK. Parental influence on human germline de novo mutations in 1,548 trios from Iceland.Nature.2017;549:519-22. [PubMed: 28959963]
• KannuP, BatemanJ, SavarirayanR. Clinical phenotypes associated with type II collagen mutations.J Paediatr Child Health.2012;48:E38-43. [PubMed: 21332586]
• KannuP, BatemanJF, RandleS, CowieS, du SartD, McGrathS, EdwardsM, SavarirayanR. Premature arthritis is a distinct type II collagen phenotype.Arthritis Rheum.2010;62:1421-30. [PubMed: 20131279]
• KannuP, IrvingM, AftimosS, SavarirayanR.Two novel COL2A1 mutations associated with a Legg-Calve-Perthes disease-like presentation.Clin Orthop Relat Res.2011;469:1785-90. [PMC free article: PMC3094608] [PubMed: 21442341]
• KozlowskiK, MarikI, MarikovaO, ZemkovaD, KuklikM. Czech dysplasia metatarsal type.Am J Med Genet A.2004;129A:87-91. [PubMed: 15266623]
• LiberfarbRM, LevyHP, RosePS, WilkinDJ, DavisJ, BalogJZ, GriffithAJ, Szymko-BennettYM, JohnstonJJ, FrancomanoCA, TsilouE, RubinBI. The Stickler syndrome: genotype/phenotype correlation in 10 families with Stickler syndrome resulting from seven mutations in the type II collagen gene locus COL2A1.Genet Med.2003;5:21-7. [PubMed: 12544472]
• MarikI, MarikovaO, ZemkovaD, KuklikM, KozlowskiK. Dominantly inherited progressive pseudorheumatoid dysplasia with hypoplastic toes.Skeletal Radiol.2004;33:157-64. [PubMed: 14730409]
• MorrisonPJ, ZnaczkoA, JanssonM. Paternal somatogonadal COL2A1 mosaicism causing recurrence of severe type 2 collagenopathy.Am J Med Genet A.2020;182:2191-4. [PubMed: 32648279]
• NagendranS, RichardsAJ, McNinchA, SandfordRN, SneadMP. Somatic mosaicism and the phenotypic expression of COL2A1 mutations.Am J Med Genet A.2012;158A:1204-7. [PubMed: 22496037]
• NakashimaY, SakamotoY, NishimuraG, IkegawaS, IwamotoY.A novel type II collagen gene mutation in a family with spondyloepiphyseal dysplasia and extensive intrafamilial phenotypic diversity.Hum Genome Var.2016;3:16007. [PMC free article: PMC4871930] [PubMed: 27274858]
• NishimuraG, HagaN, KitohH, TanakaY, SonodaT, KitamuraM, ShirahamaS, ItohT, NakashimaE, OhashiH, IkegawaS.The phenotypic spectrum of COL2A1 mutations.Hum Mutat.2005;26:36-43. [PubMed: 15895462]
• NishimuraG, NakashimaE, MabuchiA, ShimamotoK, ShimamotoT, ShimaoY, NagaiT, YamaguchiT, KosakiR, OhashiH, MakitaY, IkegawaS.Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, Torrance type.J Med Genet.2004;41:75-9. [PMC free article: PMC1757240] [PubMed: 14729840]
• OkamotoT, NagayaK, AsaiH, TsuchidaE, NoharaF, HayashiT, YamashitaA, NishimuraG, AzumaH. Platyspondylic lethal dysplasia torrance type with a heterozygous mutation in the triple helical domain of COL2A1 in two sibs from phenotypically normal parents.Am J Med Genet A.2012;158A:1953-6. [PubMed: 22711552]
• PacellaE, MalvasiA, TinelliA, LaterzaF, Dell'EderaD, PacellaF, MazzeoF, FerraresiA, MalarskaKG, CavallottiC. Stickler syndrome in Pierre-Robin sequence prenatal ultrasonographic diagnosis and postnatal therapy: two cases report.Eur Rev Med Pharmacol Sci.2010;14:1051-4. [PubMed: 21375138]
• RichardsAJ, LaidlawM, WhittakerJ, TreacyB, RaiH, BearcroftP, BaguleyDM, PoulsonA, AngA, ScottJD, SneadMP. High efficiency of mutation detection in type 1 stickler syndrome using a two-stage approach: vitreoretinal assessment coupled with exon sequencing for screening COL2A1.Hum Mutat.2006;27:696-704. [PubMed: 16752401]
• RosePS, AhnNU, LevyHP, MagidD, DavisJ, LiberfarbRM, SponsellerPD, FrancomanoCA. The hip in Stickler syndrome.J Pediatr Orthop.2001;21:657-63. [PubMed: 11521037]
• RosePS, LevyHP, LiberfarbRM, DavisJ, Szymko-BennettY, RubinBI, TsilouE, GriffithAJ, FrancomanoCA. Stickler syndrome: clinical characteristics and diagnostic criteria.Am J Med Genet A.2005;138A:199-207. [PubMed: 16152640]
• SavarirayanR, BompadreV, BoberMB, ChoTJ, GoldbergMJ, Hoover-FongJ, IrvingM, KampsSE, MackenzieWG, RaggioC, SpencerSS, WhiteKK, et al.Best practice guidelines regarding diagnosis and management of patients with type II collagen disorders.Genet Med.2019;21:2070-80. [PubMed: 30696995]
• SavarirayanR, RossiterJP, Hoover-FongJE, IrvingM, BompadreV, GoldbergMJ, BoberMB, ChoTJ, KampsSE, MackenzieWG, RaggioC, SpencerSS, WhiteKK, et al.Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia.Am J Obstet Gynecol.2018;219:545-62. [PubMed: 30048634]
• SergouniotisPI, FinchamGS, McNinchAM, SpickettC, PoulsonAV, RichardsAJ, SneadMP. Ophthalmic and molecular genetic findings in Kniest dysplasia.Eye (Lond). 2015;29:475-82. [PMC free article: PMC4816360] [PubMed: 25592122]
• SneadMP, McNinchAM, PoulsonAV, BearcroftP, SilvermanB, GomersallP, ParfectV, RichardsAJ. Stickler syndrome, ocular-only variants and a key diagnostic role for the ophthalmologist.Eye (Lond). 2011;25:1389-400. [PMC free article: PMC3213659] [PubMed: 21921955]
• SoulierM, SigaudyS, ChauC, PhilipN.Prenatal diagnosis of Pierre-Robin sequence as part of Stickler syndrome.Prenat Diagn.2002;22:567-8. [PubMed: 12124689]
• Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Type 2 collagen group. In: Spranger JW, Brill P, Superti-Furga A, Unger S, Nishimura G, eds.Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3 ed. New York: Oxford University Press. 2012a.
• Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Type 2 collagen group: achondrogenesis type 2. In: Spranger JW, Brill P, Superti-Furga A, Unger S, Nishimura G, eds.Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3 ed. New York: Oxford University Press. 2012b.
• Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Type 2 collagen group: Kniest dysplasia. In: Spranger JW, Brill P, Superti-Furga A, Unger S, Nishimura G, eds.Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3 ed. New York: Oxford University Press. 2012c.
• Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Type 2 collagen group: spondyloepiphyseal dysplasia. In: Spranger JW, Brill P, Superti-Furga A, Unger S, Nishimura G, eds.Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3 ed. New York: Oxford University Press. 2012d.
• Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Type 2 collagen group: spondyloepiphyseal dysplasia Torrance type. In: Spranger JW, Brill P, Superti-Furga A, Unger S, Nishimura G, eds.Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3 ed. New York: Oxford University Press. 2012e.
• StevensonDA, VanzoR, DamjanovichK, HansonH, MuntzH, HoffmanRO, Bayrak-ToydemirP. Mosaicism in Stickler syndrome.Eur J Med Genet.2012;55:418-22. [PMC free article: PMC3674818] [PubMed: 22522174]
• SuP, LiR, LiuS, ZhouY, WangX, PatilN, MowCS, MasonJC, HuangD, WangY. Age at onset-dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calve-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation of COL2A1.Arthritis Rheum.2008;58:1701-6. [PubMed: 18512791]
• Szymko-BennettYM, MastroianniMA, ShotlandLI, DavisJ, OndreyFG, BalogJZ, RudySF, McCullaghL, LevyHP, LiberfarbRM, FrancomanoCA, GriffithAJ. Auditory dysfunction in Stickler syndrome.Arch Otolaryngol Head Neck Surg.2001;127:1061-8. [PubMed: 11556853]
• TerhalPA, NievelsteinRJ, VerverEJ, TopsakalV, van DommelenP, HoornaertK, Le MerrerM, ZanklA, SimonME, SmithsonSF, MarcelisC, KerrB, Clayton-SmithJ, KinningE, MansourS, ElmslieF, GoodwinL, van der HoutAH, Veenstra-KnolHE, HerkertJC, LundAM, HennekamRC, MégarbanéA, LeesMM, WilsonLC, MaleA, HurstJ, AlanayY, AnnerénG, BetzRC, BongersEM, Cormier-DaireV, DieuxA, DavidA, EltingMW, van den EndeJ, GreenA, van HagenJM, HertelNT, Holder-EspinasseM, den HollanderN, HomfrayT, HoveHD, PriceS, Raas-RothschildA, RohrbachM, SchroeterB, SuriM, ThompsonEM, TobiasES, ToutainA, VreeburgM, WakelingE, KnoersNV, CouckeP, MortierGR. A study of the clinical and radiological features in a cohort of 93 patients with a COL2A1 mutation causing spondyloepiphyseal dysplasia congenita or a related phenotype.Am J Med Genet A.2015;167A:461-75. [PubMed: 25604898]
• ThamE, NishimuraG, GeibergerS, HoremuzovaE, NilssonD, LindstrandA, HammarsjöA, ArmenioM, MäkitieO, ZabelB, NordgrenA, NordenskjöldM, GrigelionieneG.Autosomal recessive mutations in the COL2A1 gene cause severe spondyloepiphyseal dysplasia.Clin Genet.2015;87:496-8. [PubMed: 25060605]
• TüysüzB, KasapB, SarıtaşM, AlkayaDU, BozlakS, KıykımA, DurmazA, YıldırımT, AkpınarE, ApakH, VuralM. Natural history and genetic spectrum of the Turkish metaphyseal dysplasia cohort, including rare types caused by biallelic COL10A1, COL2A1, and LBR variants.Bone.2023;167:116614. [PubMed: 36400164]
• UngerS, FerreiraCR, MortierGR, AliH, BertolaDR, CalderA, CohnDH, Cormier-DaireV, GirishaKM, HallC, KrakowD, MakitieO, MundlosS, NishimuraG, RobertsonSP, SavarirayanR, SillenceD, SimonM, SuttonVR, WarmanML, Superti-FurgaA. Nosology of genetic skeletal disorders: 2023 revision.Am J Med Genet A.2023;191:1164-209. [PMC free article: PMC10081954] [PubMed: 36779427]
• UngerS, KorkkoJ, KrakowD, LachmanRS, RimoinDL, CohnDH. Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal dysplasia congenita.Am J Med Genet.2001;104:140-6. [PubMed: 11746045]
• WalterK, TansekM, TobiasES, IkegawaS, CouckeP, HylandJ, MortierG, IwayaT, NishimuraG, Superti-FurgaA, UngerS. COL2A1-related skeletal dysplasias with predominant metaphyseal involvement.Am J Med Genet A.2007;143A:161-7. [PubMed: 17163530]
• WhiteKK, BompadreV, GoldbergMJ, BoberMB, ChoTJ, Hoover-FongJE, IrvingM, MackenzieWG, KampsSE, RaggioC, ReddingGJ, SpencerSS, SavarirayanR, TherouxMC, et al.Best practices in peri-operative management of patients with skeletal dysplasias.Am J Med Genet A.2017;173:2584-95. [PubMed: 28763154]
• YamamotoK, KubotaT, TakeyariS, KitaokaT, MiyataK, NakanoY, NakayamaH, OhataY, YanagiK, KanameT, OkadaY, OzonoK.Parental somatogonadal COL2A1 mosaicism contributes to intrafamilial recurrence in a family with type 2 collagenopathy.Am J Med Genet A.2020;182:454-60. [PubMed: 31854518]
• YasudaH, OhCD, ChenD, de CrombruggheB, KimJH. A novel regulatory mechanism of type II collagen expression via a SOX9-dependent enhancer in intron 6.J Biol Chem.2017;292:528-38. [PMC free article: PMC5241729] [PubMed: 27881681]
• YaziciZ, Kline-FathBM, LaorT, TinkleBT. Fetal MR imaging of Kniest dysplasia.Pediatr Radiol.2010;40:348-52. [PubMed: 20020120]
• ZanklA, ZabelB, HilbertK, WildhardtG, CuenotS, XavierB, Ha-VinhR, BonaféL, SprangerJ, Superti-FurgaA. Spondyloperipheral dysplasia is caused by truncating mutations in the C-propeptide of COL2A1.Am J Med Genet A.2004;129A:144-8. [PubMed: 15316962]
• ZhangQ, YaoR, LiQ, LiX, FengB, ChangG, WangJ, WangX.A novel homozygous variant of COL2A1 in a Chinese male with type II collagenopathy: a case report.BMC Med Genomics.2021;14:201. [PMC free article: PMC8359039] [PubMed: 34380476]